W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > March 2019

7 days left to comment (was Re: representing potential drug-drug interaction knowledge and evidence - Last commenting period for the W3C Community Group report

From: Boyce, Richard David <rdb20@pitt.edu>
Date: Thu, 14 Mar 2019 16:36:31 +0000
To: "public-semweb-lifesci@w3.org" <public-semweb-lifesci@w3.org>, "public-hclscg@w3.org" <public-hclscg@w3.org>
Message-ID: <f468460f-83c0-6d0a-ae40-4efdd03db1e2@pitt.edu>
Dear  Colleagues and Stakeholders,

This is a reminder to consider commenting (if you haven't already) on the W3C Community Group report on a  minimum information model for representing potential drug-drug interaction knowledge and evidence.

This final commenting period is extended to 3/21 (7 days from now)

If you would like to comment, here are options:

- email your  comments as a reply to this email

- add an issue on the Note's github site: https://github.com/w3c/hcls-drug-drug-interaction/issues

- reply to the dikb.org forum topic: https://forums.dikb.org/t/final-comment-periods-for-the-pddi-information-model-community-group-note/211

- Anonymously provide feedback via this qualtrics survey: https://pitt.co1.qualtrics.com/jfe/form/SV_brNsZtD8vHwPoLX


Thanks in advance!

-Rich

--

Link to the current draft:

https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/hcls-drug-drug-interaction/index.html


I can provide a Word version of the document by request to those who would like. Alternatively, you can view it locally on your machine after downloading it from github:

https://github.com/w3c/hcls-drug-drug-interaction/


Changes since last draft:

- abstract and introduction: revised to add mention of the newly written 8 detailed best practice recommendations and the prototype representations of 2 exemplar PDDIs as narrative and JSON

-  Section 2.1: revised the "Drugs Involved" subsection to include the new identifiers, added the "Operational Classification Statement" section, and removed the "Severity" section

- Added Section 2.2 A summary of recommendations related to the minimum information model that contains 8 detailed best practice recommendations using the definitions

- Section 3: revised the comments made about each of the examples of the use of the minimal information model to refer to the 8 detailed best practice recommendations

- Appendix A.1.4  -- added a small introduction to value sets and how they related to  PDDIs

- Appendix A.1.5 -- changed the straw man XML examples to more precise (though still exemplar) JSON Examples

- Throughout: indicated which sections are considered normative vs non-normative (informational)

Current abstract:

The purpose of this Community Group Note is to provide a technical and user-centered foundation for a minimum information model for information about potential drug-drug interactions. The Note provides non-ambigous definitions for 10 core information items. It also provides 8 detailed best practice recommendations related to the 10 core information items. The definitions and recommendations are shown as both narrative and prototype JSON artifacts using 2 exemplar potential drug-drug interactions. Adoption of the recommendations by developers of PDDI knowledge artifacts will improve the usefulness of the artifacts within clinical workflows. Intended downstream applications include clinical decision support, drug product label enhancement, cohort identification, and other activities relevant to protecting patients from harm from drug interactions.


Kind regards,

-Rich

--
Richard D Boyce, PhD
Associate Professor of Biomedical Informatics and Clinical and Translational Science in the Clinical and Translational
Science Institute
Director of the Informatics Core for the Center of Excellence for Natural Product- Drug Interaction Research (NaPDI)
Faculty, Center for Pharmaceutical Policy and Prescribing
Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
University of Pittsburgh
rdb20@pitt.edu<mailto:rdb20@pitt.edu>
Office: 412-648-9219
Twitter: @bhaapgh



--
Richard D Boyce, PhD
Associate Professor of Biomedical Informatics and Clinical and Translational Science in the Clinical and Translational
Science Institute
Director of the Informatics Core for the Center of Excellence for Natural Product- Drug Interaction Research (NaPDI)
Faculty, Center for Pharmaceutical Policy and Prescribing
Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
University of Pittsburgh
rdb20@pitt.edu<mailto:rdb20@pitt.edu>
Office: 412-648-9219
Twitter: @bhaapgh

Received on Thursday, 14 March 2019 16:37:01 UTC

This archive was generated by hypermail 2.4.0 : Friday, 17 January 2020 17:22:16 UTC